Arrowhead Research | ARWR - Operating Profit


Arrowhead Research reported $-141.26M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026